How to buy Xilio Therapeutics stock

Xilio Development Inc is a biotechnology business based in the US. Xilio Therapeutics shares (XLO) are listed on the NASDAQ and all prices are listed in US Dollars. Xilio Therapeutics employs 78 staff and has a market cap (total outstanding shares value) of 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Xilio Therapeutics stock price (NASDAQ: XLO)

Use our graph to track the performance of XLO stocks over time.

Xilio Therapeutics shares at a glance

• Key figures

Information last updated 2022-07-06.

Latest market close	$3.32
52-week range	$2.04 - $27.95
50-day moving average more info button	$3.05
200-day moving average more info button	$10.19
Wall St. target price	$31.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-6.56

Buy Xilio Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xilio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xilio Therapeutics price performance over time

Historical closes compared with the close of $3.32 from 2022-07-05

1 week (2022-06-29)	31.23%
1 month (2022-06-06)	9.93%
3 months (2022-04-06)	-53.17%
6 months (2022-01-06)	-76.83%

1 year (2021-07-02)	N/A
2 years (2020-07-02)	N/A
3 years (2019-07-02)	N/A
5 years (2017-07-02)	N/A

Xilio Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-28.1%
Return on equity TTM	-55.53%
Profit margin	0%
Book value	$6.09
Market capitalisation more info button	$91.2 million

TTM: trailing 12 months

Xilio Therapeutics share dividends

We're not expecting Xilio Therapeutics to pay a dividend over the next 12 months.

Xilio Therapeutics overview

Xilio Therapeutics, Inc. , a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. .

Frequently asked questions

What percentage of Xilio Therapeutics is owned by insiders or institutions?
Currently 7.379% of Xilio Therapeutics shares are held by insiders and 74.317% by institutions. How many people work for Xilio Therapeutics?
Latest data suggests 78 work at Xilio Therapeutics. When does the fiscal year end for Xilio Therapeutics?
Xilio Therapeutics's fiscal year ends in December. Where is Xilio Therapeutics based?
Xilio Therapeutics's address is: 828 Winter Street, Waltham, MA, United States, 02451 What is Xilio Therapeutics's ISIN number?
Xilio Therapeutics's international securities identification number is: US98422T1007